Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Should Patients With CLL Take Breaks From BTK Inhibitors?
HOUSTON — Bruton’s tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the treatment of chronic lymphocytic leukemia (CLL). But should patients take a break from them? At the Society of Hematologic Oncology (SOHO) 2024, two hematologist-oncologists —…
English